Calamos Advisors
TMDX icon

Calamos Advisors’s Transmedics TMDX Stock Holding History

Calamos Advisors’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,155
Closed -$2.22M – 954
2024
Q3 		$2.22M Sell
14,155
-3,692
-21% -$569K 0.01% 602
2024
Q2 		$2.69M Buy
17,847
+9,047
+103% +$1.09M 0.01% 571
2024
Q1 		$651K Buy
+8,800
New +$725K ﹤0.01% 685
2023
Q3 		– Sell
-61,343
Closed -$5.15M – 992
2023
Q2 		$5.15M Buy
61,343
+4,639
+8% +$355K 0.03% 570
2023
Q1 		$4.29M Sell
56,704
-3,528
-6% -$244K 0.02% 663
2022
Q4 		$3.72M Sell
60,232
-5,498
-8% -$292K 0.02% 720
2022
Q3 		$2.74M Buy
+65,730
New +$2.86M 0.01% 815
2021
Q4 		– Sell
-118,141
Closed -$3.91M – 1166
2021
Q3 		$3.91M Buy
+118,141
New +$3.61M 0.02% 676

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Calamos Advisors's TMDX Position: Q4 2024 in Review

Calamos Advisors sold out of Transmedics (TMDX) in Q4 2024, closing a stake of 14,155 shares — an estimated $2.22M sold.

Calamos Advisors first reported a position in TMDX in Q3 2021 and held it in 8 quarters. The position peaked at $5.15M in Q2 2023. 315 funds tracked by Wall St. Rank hold TMDX as of Q4 2024.

  • Calamos Advisors reported no remaining Transmedics position as of Q4 2024 after selling out during the quarter.
  • Calamos Advisors sold 14,155 Transmedics shares in Q4 2024, an estimated $2.22M.
  • Calamos Advisors first reported a position in Transmedics in Q3 2021 and held it in 8 quarters.
  • Calamos Advisors's Transmedics position peaked at $5.15M in Q2 2023.
  • 315 funds tracked by Wall St. Rank held Transmedics as of Q4 2024.

Based on Calamos Advisors's 13F filing for Q4 2024, filed 24 Jan 2025.